Trial Profile
A Phase II Randomized, Placebo Controlled, Double-blind, Four Arms Dose-ranging Study to Evaluate the Efficacy and Safety of SHR0302 Compared to Placebo in Patients With Moderate to Severe Active Crohn's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Mar 2023
Price :
$35
*
At a glance
- Drugs Ivarmacitinib (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors Reistone Biopharma
- 23 May 2022 Status changed from active, no longer recruiting to completed.
- 26 Jul 2021 Planned End Date changed from 1 Oct 2021 to 31 Dec 2021.
- 26 Jul 2021 Planned primary completion date changed from 1 Jun 2021 to 15 Sep 2021.